{"id":"NCT04230213","sponsor":"Pfizer","briefTitle":"A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis","officialTitle":"A RANDOMIZED COMPARATIVE STUDY ASSESSING THE SWITCHING BETWEEN PF-06410293 AND HUMIRA (REGISTERED) IN COMBINATION WITH METHOTREXATE IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-01-13","primaryCompletion":"2021-06-22","completion":"2021-06-22","firstPosted":"2020-01-18","resultsPosted":"2022-08-22","lastUpdate":"2024-02-22"},"enrollment":455,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"PF-06410293","otherNames":[]},{"type":"DRUG","name":"adalimumab","otherNames":["Humira ®"]}],"arms":[{"label":"Treatment Arm 1","type":"EXPERIMENTAL"},{"label":"Treatment Arm 2","type":"ACTIVE_COMPARATOR"}],"summary":"The study will assess the impact of pharmacokinetics (PK), safety and immunogenicity after switches between PF-06410293 and adalimumab and with continuous dosing with adalimumab in combination with methotrexate in subjects with moderately to severely active rheumatoid arthritis.","primaryOutcome":{"measure":"Maximum Observed Serum Concentration (Cmax) of Adalimumab","timeFrame":"Pre-dose, 48, 72, 96, 144, 240 and 336 hours post dose on Day 211 (Week 30)","effectByArm":[{"arm":"Switching Arm: Humira and PF-06410293 (Adalimumab)","deltaMin":9.156,"sd":97},{"arm":"Non-switching Arm: Humira (Adalimumab)","deltaMin":8.974,"sd":97}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":null},"locations":{"siteCount":72,"countries":["United States","Bosnia and Herzegovina","Bulgaria","Czechia","Lithuania","Poland","Russia","Serbia","South Africa","Ukraine"]},"refs":{"pmids":["38251497"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=B5381012"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":445},"commonTop":["SARS-CoV-2 test positive","COVID-19","Injection site reaction","Erythema","Urinary tract infection"]}}